Fengwo shares' Shanghai Main Board IPO "terminated," gasoline engine turbocharger sales rank second in the domestic market.
On June 30th, Ningbo Fengwo Turbochargers Technology Co., Ltd. (referred to as Fengwo Corporation) changed its IPO review status on the Shanghai Stock Exchange Main Board to "terminated".
On June 30, Ningbo Fengwo Turbocharging Technology Co., Ltd. (referred to as Fengwo Co., Ltd.) underwent a status change in IPO review on the Shanghai Stock Exchange Main Board to "terminated." This is because Fengwo Co., Ltd. and its sponsor withdrew their application for listing, leading to the termination of the IPO review by the Shanghai Stock Exchange in accordance with relevant regulations.
According to the prospectus, Fengwo Co., Ltd.'s main business is the research, development, manufacturing, and sales of turbochargers. The company also expands into the electric turbocharger and air suspension core component fields. Their products mainly target the automotive front-end market and are used in various passenger car gasoline engines and hybrid powertrains.
Since its establishment, the company has focused on turbocharger products, catering to the passenger car market and constantly developing and iterating based on customer needs. They have become a core component supplier for well-known car manufacturers such as Chery Group, Geely Group, Guangzhou Automobile Group, BYD Company Limited, and Changan Group, breaking the monopoly of international giants in the domestic gasoline engine turbocharger market.
Since 2022, the company's market share and ranking have continuously increased. In 2024, the company sold 2.2122 million turbochargers for passenger car gasoline engines, accounting for 15.3% of the national market share, ranking second in the domestic market and first among domestic enterprises.
With over a decade of continuous technical development and production experience, the company has accumulated rich patents and non-patent technologies. They have the ability to design overall matching solutions in cooperation with car manufacturers, synchronous research and development, and automated production. Their capabilities in product development, production management, quality control, and delivery speed have been highly recognized by customers.
During the reporting period, the company's main business income composition based on product and service types is as follows:
The company has been recognized as a national-level "small giant" enterprise specializing in new and high-tech industries and a Zhejiang province-level high-tech small and medium-sized enterprise. In 2023, they were awarded the title of "Excellent Supplier" by BYD Company Limited. They also received various awards from Guangqi PAAICHI, CHERY AUTO, and BYD Company Limited during 2021-2024. As of the end of the reporting period, the company owns 99 patents, including 16 invention patents and 83 utility model patents.
Financially, in the years 2022, 2023, 2024, and in the first half of 2025, the company achieved operating revenues of approximately 1.399 billion RMB, 1.598 billion RMB, 2.067 billion RMB, and 997 million RMB respectively. During the same periods, the net profits attributable to the owners of the parent company were 1.19 billion RMB, 1.30 billion RMB, 2.04 billion RMB, and 1.14 billion RMB respectively.
Related Articles
.png)
CSPC PHARMA (01093) has received a $25 million research and development milestone payment from AstraZeneca under a strategic collaboration and licensing agreement.

US Stock Market Move | Concept stocks related to optical communication generally fell, with Applied Optoelectronics (AAOI.US) dropping more than 6%.

GUMING (01364) spent HK$5.758 million to repurchase 288,000 shares on July 10th.
CSPC PHARMA (01093) has received a $25 million research and development milestone payment from AstraZeneca under a strategic collaboration and licensing agreement.
.png)
US Stock Market Move | Concept stocks related to optical communication generally fell, with Applied Optoelectronics (AAOI.US) dropping more than 6%.

GUMING (01364) spent HK$5.758 million to repurchase 288,000 shares on July 10th.

RECOMMEND





